Syndax Pharmaceuticals Inc.’s eight-year struggle as a biotech has reached a crescendo; the developer of epigenetic modifiers is ready to begin a late-stage pivotal trial of its lead drug candidate now that it has secured financing from both private investors and the National Cancer Institute.
Syndax Begins New Chapter As A Late-Stage Drug Developer
A recent influx of cash to the small biotech will allow Syndax to develop its oncology asset on its own, beginning with a Phase III trial and potentially continuing to U.S. commercialization.